Status:
ACTIVE_NOT_RECRUITING
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Lead Sponsor:
RenJi Hospital
Conditions:
Breast Cancer Female
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
Brief Summary
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
Eligibility Criteria
Inclusion
- Female, Aged ≥18 and ≤70 years
- Histologically confirmed invasive HER2 positive breast cancer, early disease(Stage ⅡA-Ⅲ)
- Subjects with at least one evaluable lesion
- ECOG 0-1
- Adequate organ function
Exclusion
- Metastatic disease (Stage IV)
- Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
- Treated or treating with T-DM1, lapatinib and neratinib before study entry
- History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation
- Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial
- Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test. Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
- Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study
Key Trial Info
Start Date :
June 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2026
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04126525
Start Date
June 18 2019
End Date
November 1 2026
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital
Shanghai, China